Tier 2 — strong

Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women

Yuichiro Fukamizu, Yoshiaki Uchida, Akari Shigekawa, Toshiya Sato, Hisayuki Kosaka, Takanobu Sakurai
Scientific Reports 2022 12:14442

Bibliography

PubMed
PMID 36002548
PubMed Central
PMC9400576
DOI
10.1038/s41598-022-18272-y
Funding
The study was conducted at Pharma Foods Co., Ltd. and funded by Mitsubishi Corporation Life Sciences Limited, which also provided the NMN-containing and placebo test foods. The paper states that Mitsubishi Corporation Life Sciences Limited was not involved in conduct or data analysis.
Competing interests
Yuichiro Fukamizu, Yoshiaki Uchida, Akari Shigekawa, Toshiya Sato, and Takanobu Sakurai were employees of Mitsubishi Corporation Life Sciences Limited. Hisayuki Kosaka was a physician at Takaishi Fujii Hospital and served as principal investigator.

Study snapshot

DesignRandomized, double-blind, placebo-controlled parallel-group safety trial.
ModelHealthy adult men and women aged 20–65 years.
Samplen=31; 16 NMN and 15 placebo.
Interventionβ-NMN 1250 mg once daily versus placebo.
Duration4 weeks.
EndpointsAdverse events; Anthropometry and vital signs; Hematology and blood chemistry; Urinalysis; Body composition

What the study showed, in plain terms

This trial tested a substantially higher NMN dose than most early studies: 1,250 mg once daily for four weeks in healthy adults.

Across the prespecified clinical and laboratory safety measures, the investigators did not identify changes outside expected physiological variation or severe adverse events. The short duration and small sample mean that rare or delayed harms remain unresolved.

Key findings

  • No severe adverse events were reported during four weeks of 1250 mg/day β-NMN.
  • Anthropometric, hematologic, biochemical, urine and body-composition measures did not show clinically problematic treatment-related changes.
  • The study provides short-term high-dose tolerability data, not evidence of efficacy.

What this study can and cannot tell us

The study included only 31 healthy adults and lasted four weeks. It can inform short-term tolerability of 1250 mg/day but is too small and brief to detect rare, delayed, cumulative, or population-specific harms. Five of six authors were employees of the company that funded the study and supplied the test foods.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology